AIM ImmunoTechAIM -5.41%37 Buyback Yield % is -145.16 as of Jul. 03, 2026. GuruFocus rates AIM with a GF Score™ of 37/100 and a GF Value™ of $2.63 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 744 Biotechnology companies, AIM ImmunoTech ranks worse than 93.01% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for AIM ImmunoTech's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM vs RVPH, BOLT, ERNA: Buyback Yield % Comparison
For the Biotechnology subindustry, AIM ImmunoTech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a Buyback Yield % of -145.16 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on AIM ImmunoTech and its competitors. According to the industry distribution chart, AIM ImmunoTech ranks #692 out of 744 companies in the Biotechnology industry, placing it in the top 93%.
Is AIM ImmunoTech's Buyback Yield % too high?
AIM ImmunoTech's current Buyback Yield % is -145.16. Based on the distribution chart, AIM ImmunoTech ranks #692 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Buyback Yield % compare to RVPH and BOLT?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #692 out of 744 companies for Buyback Yield %. This places AIM ImmunoTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Buyback Yield % is -145.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.63, compared to a current price of $0.28 — trading 89.4% below its estimated fair value. The current Buyback Yield % is -145.16. AIM ImmunoTech's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Buyback Yield % is -145.16 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.28 is trading 89.4% below its estimated GF Value™ of $2.63.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
Buyback Yield %: -145.16
GF Value™: $2.63 vs. price of $0.28 (89.4% below fair value)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
37GF Score
Get the complete analysis for AIM
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
